HYPERKINETIC BOYS AND THEIR SIBLINGS AS YOUNG ADULTS

这是一项成人跟踪研究的最后阶段，研究对象为患有 多动症/注意缺陷障碍(香港/ADD)， 非过动症全兄弟及其非过动症前辈 同学们。所有患者最初在4岁至12岁时被转诊至 爱荷华大学儿童精神病学门诊。样品 包括：a)早期服药组(1967-1972年至 哌醋甲酯)；b)过渡性药物基团(指 1972-1975年，主要用哌醋甲酯治疗)；c)过渡期 未用药组(也指1972-1975年间，由于 医生偏好，未使用精神药物治疗)；以及d)a 晚期未服药组(1976-1978年间就诊，未接受治疗 精神药物)。 这些研究的总体目的是(A)描述成人的结果 与亲生兄弟和亲生兄弟的结果进行比较 同学控制；以及(B)确定这些主题和环境 预测结果差异的特征。计划中的 比较将测试以下变量对结果的影响 多动症和攻击性；兴奋剂治疗；对 药物；以及物质使用/滥用。建立方法以实现 预测和诊断残留的ADD/成人MBD将是一项特殊的 担忧。 在1988年和1989年，对155名21至23岁的早期用药患者进行了随访 先驱者和66个兄弟已经完成。此外，大多数 过渡和已故团体(72名先知、24名兄弟和51名 同学)也在21到23岁之间完成了他们的评估。最后， 早期用药组的71名先证者和他们的31名兄弟 年龄在28岁到32岁之间。在拟议的两年赠款期间，数据 将对21至23岁的样本进行分析。分析 适用于28至32岁的部分样本 受试者和兄弟也将被进行。

This is the final phase of an adult follow-up study of boys with Hyperkinetic/Attention Deficit Disorder (HK/ADD), of their nonhyperkinetic full brothers, and of their nonhyperkinetic former classmates. All patients were originally referred at ages 4 to 12 to the University of Iowa child psychiatry outpatient clinic. The samples include: a) an Early Medicated group (referred between 1967-1972 and methylphenidate); b) a Transitional Medicated group (referred between 1972-1975 and treated primarily with methylphenidate); c) a Transitional Unmedicated group (also referred between 1972-1975,ut, because of physician preference, not treated with psychotropic drugs); and d) a Late Unmedicated group (referred between 1976-1978 and not treated with psychotropic drugs). The general aim of these studies is to (a) describe the adult outcomes of HK/ADD and compare them with the outcome of biological brothers and classmate controls; and (b) to identify those subject and environmental characteristics that predict differences in outcome. Planned comparisons will test the effects on outcome of such variables as hyperactivity and aggression; stimulant drug treatment; response to medication; and substance use/abuse. Establishing methods for predicting and diagnosing residual ADD/adult MBD will be a special concern. In 1988 and 1989, the 21-to-23-year-old follow-up of 155 Early Medicated probands and 66 brothers was completed. In addition, the majority of the Transitional and Late groups (72 probands, 24 brothers, and 51 classmates) also completed their evaluations at ages 21 to 23. Finally, 71 probands in the Early Medicated group an 31 of their brothers were evaluated at ages 28 to 32. In the proposed two-year grant period, data analysis for the 21 to 23 year old samples will be conducted. Analyses that are appropriate for the partial sample of 28 to 32 year old subjects and brothers will also be conducted.